Pharma has over $500B in capital for deals

Off Biotech, biotechnology, Business, drug development, drug prices, drug pricing, FDA, finance, genetics, Health, Human Health, Life Sciences, Medicine, Pharma, Pharmaceuticals, Politics, research, Science and Research, The Readout

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Today we ponder, how much will the advisory committee meeting for Lilly’s donanemab matter? Send me your thoughts, and as always, any ideas or tips: [email protected].

Read the rest…

Read Original Article: Pharma has over $500B in capital for deals »

About The Author